$ cat ./records/gates-foundation-awards-38-million-polio-vaccine-grant-to-takeda-2016.txt
Gates Foundation Awards $38 Million Polio Vaccine Grant to Takeda
[RECORD.TXT] · cat --full
The Gates Foundation awarded a $38 million grant to Japan's Takeda Pharmaceutical to expand polio vaccine manufacturing capacity and support global vaccine access initiatives. The grant supported Takeda's production of inactivated poliovirus vaccine (IPV) and contributed to the stockpile maintained by UNICEF and GPEI for emergency and routine immunisation programmes in high-risk countries.
Source: https://www.fiercepharma.com/pharma-asia/takeda-gains-38m-polio-grant-from-gates-foundation
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Backs 14-Million-Person Yellow Fever Campaign in Angola and DRC
Next →
Funded container-based sanitation with waste-to-energy processing at Kakuma refugee camp, Kenya
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.